These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
64. Antisense strategies: functions and applications in immunology. Varga LV; Tóth S; Novák I; Falus A Immunol Lett; 1999 Aug; 69(2):217-24. PubMed ID: 10482355 [TBL] [Abstract][Full Text] [Related]
65. Small non-coding RNA therapeutics for cardiovascular disease. Shah AM; Giacca M Eur Heart J; 2022 Nov; 43(43):4548-4561. PubMed ID: 36106499 [TBL] [Abstract][Full Text] [Related]
66. [Recent progress and prospect in oligonucleotide therapeutics]. Yoshioka K; Kuwahara H; Nishina K; Nagata T; Yokota T Nihon Rinsho; 2015 Jun; 73(6):1057-65. PubMed ID: 26065142 [TBL] [Abstract][Full Text] [Related]
67. The therapeutic potential of LNA-modified siRNAs: reduction of off-target effects by chemical modification of the siRNA sequence. Fluiter K; Mook OR; Baas F Methods Mol Biol; 2009; 487():189-203. PubMed ID: 19301648 [TBL] [Abstract][Full Text] [Related]
68. Introduction and History of the Chemistry of Nucleic Acids Therapeutics. Gait MJ; Agrawal S Methods Mol Biol; 2022; 2434():3-31. PubMed ID: 35213007 [TBL] [Abstract][Full Text] [Related]
69. Avian picornaviruses: molecular evolution, genome diversity and unusual genome features of a rapidly expanding group of viruses in birds. Boros Á; Pankovics P; Reuter G Infect Genet Evol; 2014 Dec; 28():151-66. PubMed ID: 25278047 [TBL] [Abstract][Full Text] [Related]
70. Inhibition of mouse hepatitis virus multiplication by antisense oligonucleotide, antisense RNA, sense RNA and ribozyme. Mizutani T; Hayashi M; Maeda A; Sasaki N; Yamashita T; Kasai N; Namioka S Adv Exp Med Biol; 1993; 342():129-35. PubMed ID: 8209719 [TBL] [Abstract][Full Text] [Related]
71. RNA therapeutics for metabolic disorders. Vu TD; Lin SC; Wu CC; Chu DT Prog Mol Biol Transl Sci; 2024; 203():181-196. PubMed ID: 38359998 [TBL] [Abstract][Full Text] [Related]
73. Making sense of antisense. Murakami A Trends Mol Med; 2001 Oct; 7(10):430-1. PubMed ID: 11597507 [No Abstract] [Full Text] [Related]
74. Recent development of 3C and 3CL protease inhibitors for anti-coronavirus and anti-picornavirus drug discovery. Ramajayam R; Tan KP; Liang PH Biochem Soc Trans; 2011 Oct; 39(5):1371-5. PubMed ID: 21936817 [TBL] [Abstract][Full Text] [Related]
75. Therapeutic antisense and ribozymes. Rossi JJ Br Med Bull; 1995 Jan; 51(1):217-25. PubMed ID: 7767645 [TBL] [Abstract][Full Text] [Related]
77. Sequence analysis of a duck picornavirus isolate indicates that it together with porcine enterovirus type 8 and simian picornavirus type 2 should be assigned to a new picornavirus genus. Tseng CH; Tsai HJ Virus Res; 2007 Nov; 129(2):104-14. PubMed ID: 17686542 [TBL] [Abstract][Full Text] [Related]
78. Antisense treatments for biothreat agents. Warfield KL; Panchal RG; Aman MJ; Bavari S Curr Opin Mol Ther; 2006 Apr; 8(2):93-103. PubMed ID: 16610760 [TBL] [Abstract][Full Text] [Related]
79. DNA and RNA derivatives to optimize distribution and delivery. Wickstrom E Adv Drug Deliv Rev; 2015 Jun; 87():25-34. PubMed ID: 25912659 [TBL] [Abstract][Full Text] [Related]